Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that BRAF p.V600E status confers therapeutic sensitivity to Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin in patients with Colorectal Adenocarcinoma.
The European Medicines Agency (EMA) has authorized cetuximab in combination with encorafenib and FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) for the first-line treatment of patients with BRAF V600E mutant metastatic colorectal cancer.
This statement is based on a regulatory approval from the European Medicines Agency:
Erbitux is indicated for the treatment of adult patients with BRAF V600E mutant metastatic colorectal cancer in combination with encorafenib and FOLFOX for the first line treatment.